Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for patients with triple-negative breast cancer.

NCT Number	NCT07256964
Lead Sponsor	Henan Cancer Hospital
Conditions	TNBC - Triple-Negative Breast Cancer
Enrollment	216 participants
Start Date	2025-11-26
Primary Completion	2028-12-31 (estimated)
Study Completion	2033-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-02